RE:RE:RE:RE:RE:RE:RE:News: CEO ExitsEoganacht wrote: Right. As of right now Shawn Shirazi is the only member of Theralase's Cinical Research Team. As of tomorrow at 5:00 pm there will be no Clinical Research Team. Unless, of course, we get a news release tomorrow morning announcing that a clinical research coordinator has been hired.
CancerSlayer wrote: Eoganacht wrote: It looks like he was hired for the new COO position whose mandate was to bring about triple digit revenue growth of the Company’s current medical devices.
I'm guessing Shawn quit or was let go this week and John Trikola has agreed to also fill in as interim CEO until they find a new one - just like Arkady Mandel did when Roger had to step down as CEO.
Vikingstock wrote: I hope they focus on the trials. Looks like he has been brought in for the laser division, temp ceo. I don't think most investors are here for the laser division. Better hire a seasoned pharma c eo to get the trials done and compounds to martket or sell the company.
Definitely looks like a business-oriented hire to help drive sales for the cool laser division. Despite Shawn's perceived shortcomings, his bio indicates he was the primary/sole expert in drug & clinical trial development who also has had plenty of experience in dealing with regulatory authorities. Though his departure (resigned, let go?) may end up being a positive, it's not very comforting to see what his replacement's bio brings to the table...a complete void in all trial matters (design adaptations, fast track/BTD requirements, data review, etc.). So who becomes the company's trial leader/primary contact with the FDA moving forward? Dr. Mandel? At least now we have our reason for the quarterly news delay...let's hope there's positive news to come. JMHO.
Makes sense that a CRC would already be hired or is in the process of being hired, especially if Shawn left on unfriendly terms. If this were an amicable exit, I imagine he would assist with any needed/trial-related transitions in the interim (as a consultant)....but this was not explicitly stated. In my opinion, he more than likely did not leave on the best of terms, especially when considering where we currently stand with the trial. Just need some trial data assurances sooner than later.